Baccini, M., 535
Baguley, B. C., 1
Balicki, A., 299
Balzarotti, M., 245, 453
Bartolini, P., 75
Bastounis, E., 129
Bergoc, R., 55*
Biagetti, S., 157
Biggeri, A., 535
Bilir, A., 195, 225
Boiardi, A., 245, 453
Boratynski, J., 415
Brody, J. L., 35
Bryant, I., 179
Budzynska, R., 415

Caciagli, B., 143
Calatozzolo, C., 453
Camoutsis, C., 129
Campos-Aranda, M., 211
Capaccioli, S., 143
Caprodossi, S., 157
Carpagnano, F., 375
Carpagnano, G. E., 375
Castagnini, C., 535
Cavalieri, D., 535
Cawkwell, L., 497
Chak, E. C. W., 273
Chandra Mohan, K. V. P., 167
Chang, K. T., 325
Chang, S., 383
Chang, Y., 479
Chaturvedi, R., 587
Chatzaki, E., 281
Chen, D., 313
Chen, G. G., 273
Chen, Y.-H., 75
Chène, P., 549
Chiang, C.-T., 119
Chiara, G. D., 157
Ching, L.-M., 1
Chiu, C.-C., 479
Chueh, P.-J., 299
Chyczewska, E., 49, 445
Cianchi, F., 535
Ciusani, E., 245, 453
Cocca, C., 55*
Comert, E., 423
Crescenti, E., 55*
Cricco, G., 55*
Croci, D., 245, 453
Croci, M., 55*
Curci, C., 375
Czerwenka, K., 465

Dalay, N., 43
De Filippo, C., 535
de Grazia, U., 453
DeGregorio, M. W., 251
Dharmarajan, A., 67
Di Gioia, G., 375
Ding, X.-Q., 313
Dirven, C. M. F., 471
Dolara, P., 535
Donnini, M., 143
Drew, P. J., 497
Dubaele, S., 549
Duydu, Y., 423

Edakuni, N., 235
Elhan, A., 423
Endo, K., 57

Fanelli, M., 157
Fang, K., 479
Feng, X., 405
Fontana, F., 245
Foschino Barbaro, M. P., 375
Fujii, H., 85
Furukawa, Y., 85

Gal, S., 35
Galluzzi, L., 157
Garg, V. K., 587
Geldof, A. A., 471
Gelmini, S., 535
Geromichalos, G. D., 129
Gerritsen, W. R., 471
Getoff, N., 389
Ghoshal, U. C., 437
Gilleron, P., 107
Goksel, G., 225
Goossens, J.-F., 107
Goto, H., 15
Goya, S., 489
Gupta, B., 351
Gutiérrez, A., 55*
Guvenc, G., 423

Hamada, J., 217
Hamatake, M., 333
Hara, Y., 167
Harada, M., 341
Harasym, T. O., 361
Harris, A. L., 35
Harvie, P., 361
Hassan, N. M. M., 217
Heinze, G., 465
Hénichart, J.-P., 107
Hiraike, H., 431
Hiraike, O., 431
Hirst, D. G., 569
Houhouli, K., 281
Houssin, R., 107
Hwang, H., 479

Idema, S., 471
Ikuta, K., 235
Ilangovan, R., 67
Inoue, K., 85
Inoue, N., 217
Irimura, T., 289
Ishii, K., 57
Issever, H., 43
Itoh, K., 341
Izumi, T., 85
Izycki, T., 49, 445
 
 
 
 

Kadehci, Z., 43
Kakolyris, S., 281
Kanagaraj, P., 67
Kang, G. H., 205
Kang, S.-B., 205
Kano, Y., 85
Kanska, U., 415
Karamanakos, P., 129
Karami-Tehrani, F., 575
Kashiwazaki, H., 217
Katsaros, D., 395
Kawase, I., 489
Kelland, L. R., 97
Kijima, T., 489
Kim, B. S., 325
Kim, C., 299
Kim, J. W., 205
Kim, M. O., 325
Kim, S. H., 325
Kobayashi, H., 85
Kontos, M., 129
Koukoulitsa, C., 129
Kouso, H., 333
Kucucuk, S., 43
Kumada, H., 57
Kumagai, T., 489
Kumar, S., 437
Kumaraguruparan, R., 167
Kuniyoshi, Y., 333
Kuo, K.-L., 119
Kutner, A., 517

Lamfers, M. L. M., 471
Landini, I., 143
Lant, N., 97
Lapucci, A., 143
Lee, H.-P., 205
Lee, S., 325
Lee, T.-H., 325
Lemonie, A., 107
Leodolter, S., 465
Levchenko, T. S., 351
Li, C.-H., 479
Li, H., 261, 405
Li, H., 405
Li, S., 313
Lin, J.-K., 119
Lind, M. J., 497
Lin-Shiau, S.-Y., 119
Liu, H. C., 273
Lu, L., 395
Luceri, C., 535
Lulli, M., 143
Luzzatto, L., 535
Lyrantzopoulos, N., 281

Maciag, K., 535
Maehara, Y., 333
Magnani, M., 157
Majhi, U., 527
Malone, P. R., 35
Mano, H., 85
Marchisano-Karpman, C., 251
Marcinkowska, E., 27
Marras, C., 245
Martí, G., 55*
Matsumori, Y., 15
Matsumoto, Y., 431
Matsumura, A., 57
Matsuoka, H., 489
Matsuoka, K., 341
Matthaios, D., 281
Mayer, L. D., 361
Mazzei, T., 143
Medina, V., 55*
Messerini, L., 535
Milczarek, M., 517
Millet, R., 107
Miloussis, A., 281
Minaguchi, T., 431
Minami, S., 489
Mine, T., 341
Mini, E., 143, 535
Mitra, A. K., 587
Mittal, B., 437
Miyagi, T., 289
Miyamoto, Y., 431
Mizoguchi, J., 314
Mohamad, N., 55*
Moon, E.-Y., 507
Morganti, M., 143, 535
Mori, K., 85
Moriuchi, T., 217
Morré, D. J., 299, 557
Morré, D. M., 299, 557
Muguruma, H., 235
Murai, T., 217

Nagasaka, K., 431
Nagini, S., 167
Nakagawa, S., 431
Nakataki, E., 15, 235
Napoli, C., 535
Naumnik, W., 49, 445
Nevozhay, D., 415
Nicoll, K., 97
Nikolopoulou, M., 129
Nobili, S., 143, 535
Noguchi, M., 341
Nomura, H., 289
Núñez, M., 55*

Obata, Y., 341
Oda, K., 431
Oda, S., 333
Odgerel, T., 85
Ohara, Y., 57
Ohba, T., 333
Oikawa, M., 57
Öktem, G., 195, 225
Omay, S. B., 195
Opolski, A., 415
Orlando, C., 535
Osaki, T., 489
Osoegawa, A., 333
Ossolinska, M., 49, 445
Ozcelik, H., 43

Palladino, G. P., 375
Panjehpour, M., 575
Papatheodorou, K., 281
Papucci, L., 143
Park, G., 179
Park, N.-H., 205
Park, Y. B., 325
Pascual-Carpe, F., 211
Pelicci, P. G., 157
Peng, D., 261
Penington, D. J., 179
Perna, F., 143
Pitfield, S. E., 179
Pommery, N., 107
Puopolo, M., 395
 

Saip, P., 43
Sakai, T., 57
Salerno, F., 375
Salmaggi, A., 245, 453
Sato, T., 57
Saydam, G., 225
Schiavone, N., 143
Schittl, H., 389
Schremmer, M., 465
Schuster, E., 465
Seino, A., 217
Selvaluxmi, G., 527
Selvi, N., 195
Shaida, N., 35
Sharma, M., 587
Shibata, Y., 57
Shin, M. J., 325
Sigurdson, A. J., 383
Singh, N., 587
Smith, L., 497
Sobrero, A., 143
Sone, K., 431
Sone, S., 15, 235
Song, J.-H., 507
Song, Y.-S., 205
Sonke, G. S., 383
Spanevello, A., 375
Strom, S. S., 383
Suekane, S., 341
Superat, K., 27
Susumu, N., 289
Suzen, H. S., 423
Suzuki, A., 289
Suzuki, M., 489
Suzuki, N., 289
Sweeney, A. M., 383
Swidzinska, E., 445

Tachibana, I., 489
Tada, M., 217
Taira, M., 289
Takahashi, Y., 217
Takeda, Y., 489
Takenaka, T., 333
Taketani, Y., 431
Takizawa, S., 431
Tamada, Y., 289
Tan, D., 75
Tang, X., 557
Tani, M., 235
Tardi, P. G., 361
Tempestini, A., 143
Tentes, A., 281
Tigli, H., 43
Tonelli, F., 535
Tong, D., 465
Tong, M. C. F., 273
Tonini, G., 535
Torchilin, V. P., 351
Toti, S., 535
Trafalis, D. T. P., 129
Tsai, Y.-J., 119
Tsaroucha, A., 281
Tsuboi, K., 57
Tsunoda, S., 85
Tsuruga, T., 431
Turanli, M., 423

Ueda, E., 75
Ueda, K., 489
Uehara, H., 235
Uysal, A., 195, 225

Valanzano, R., 535
van der Jagt, M., 471
Vandertop, W. P., 471
van Hasselt, C. A., 273
Vatansever, S., 195
Vidjaya Letchoumy, P., 167
Vijayababu, M. R., 67
Vijayalakshmi, N., 527
Vincente-Ortega, V., 211
Vlantis, A. C., 273

Wainscoat, J. S., 35
Walker, A. M., 75
Wang, A.-X., 313
Wang, J., 313
Wang, L., 261, 405
Wang, L.-C., S., 1
Watanabe, M., 431
Watson, M. B., 497
Wedge, S. R., 15
Wei, M. X., 107
Welham, K. J., 497
Weng, M.-S., 119
Wiedocha, A., 27
Wietrzyk, J., 415, 517
Wiley, A., 395
Witort, E., 143
Wlodarczyk, N., 107
Woon, S.-T., 1
Wu, W., 75
Wurz, G. T., 251

Yagiz, K., 299
Yamada, A., 341
Yamamoto, K., 57
Yamamoto, T., 57
Yamazaki, Y., 217
Yañez-Gascón, J., 211
Yang, K.-H., 507
Yano, S., 15, 235
Yano, T., 431
Yao, K., 261, 405
Yasugi, T., 431
Yavasoglu, A., 225
Yazici, H., 43
Yi, H.-M., 261
Yohena, T., 333
Yokota, J., 235
Yokota, S., 489
Yoshida, K., 341
Yoshida, M., 489
Yoshino, I., 333
Yu, D. H., 325
Yu, H., 395
Yurtseven, M. E., 195

Zeillinger, R., 465
Zhang, 217
Zhang, H.-J., 261, 405
Zhao, M., 261
Zhou, W., 405
Zhu, B., 405
 

B16F10 melanoma, 211
Bak, 273
Bax, 273
BCAT1, 405
Bcl-2, 507
Bcl-2 protein, 67
BCNU, 453
Biomarkers, 497
Black tea, 119
Black tea polyphenols, 167
Boron-10 (¹⁰B), 57
Boron neutron capture therapy (BNCT), 57
Brain tumor, 351
BRCA gene mutations, 43
Breast cancer, 129, 179, 195, 251, 465, 497, 587
Breast cancer spheroid, 225
Bronchioloalveolar carcinoma, 489

C57BL/6J, 211
Calcitriol and its analogs, 517
cAMP, 575
Cancer, 299, 415, 557
Cancer vaccine, 341
Capecitabine, 281
Carrier, 27
Case-control studies, 383
Caspase-3, 507
Cell cycle, 453
Cell cycle regulatory proteins, 75
Cell-free DNA, 35
Cell polarity, 431
Cervical cancer, 527
Chemoprevention, 167
Chemotherapy, 49, 195, 445, 497
Chlorambucil, 129
Cisplatin, 85, 479, 497, 517
Clear cell adenocarcinoma, 289
Colon cancer, 107
Colon carcinoma, 143
Colorectal cancer, 361
Colorectal cancer prognosis, 535
Combination chemotherapy, 361
Combined antitumor therapy, 517
Conjugates, 415
Connexin-43, 225
Cyclin D, 75
Cyclin D1, 527
Cyclin D1/p16/Rb pathway, 527
Cyclin-dependent kinases 2 and 4, 75
CYP17 polymorphism, 43
CYP1A1, 437
CYP1A1 polymorphism, 587
Cysteaminylphenol, 97

DDX18, 549
DEAD box, 549
Differentiation, 273
1,25 Dihydroxy vitamin D₃, 75
Dimethylbenzanthracene (DMBA), 251
DMBA/TPA, 325
DMXAA, 1
Docetaxel, 225, 281, 517
Docking, 129
Doxorubicin, 225
Drug administration schedule, 143
Drug delivery, 27
Drug resistance, 143
Dysplasia, 217

ECTO-NOX, 299
EGFR, 15
Endometrial cancer, 205, 431
eNOS, 195
ENOX2, 557
Epidermal growth factor receptor, 489
ErbB4, 179
Esophageal cancer, 437
Estramustine phosphate, 341
Estrogen receptor, 129
Estrogens, 383
Exhaled breath condensate, 375 

Gandolinium-157 (¹⁵⁷Gd), 57
Gefitinib, 15, 489
Gemcitabine, 281
Gene delivery, 351
Gene expression, 143, 405, 465, 535
Glioma, 245, 453, 471
Green tea, 119
GSTM1, 423
GSTT1, 423

Hamster buccal pouch carcinogenesis, 167
Head and neck cancer, 423
Hela cell, 507
Helicase, 549
HepG2 cells, 119
Histone deacetylase, 453
hK14 promoter, 325
Homo-aza-steroid alkylating esters, 129
HOX, 217
HPV, 527
HPV16 E6/E7, 325
Hug1-1, 431
Human breast cancer cell lines, 575
Human non-small cell lung cancer cells, 479
Hydroxycamptothecin (HCPT), 313
Hypermethylation, 205

IGFBP-3, 49
IGF-I, 49
IL-2, 375
Ileum, 569
Imatinib mesylate, 517
Immunotherapy, 341
INF-a, 211
INF-g, 1
iNOS, 195
Insulin-like growth factor binding protein-3 (IGFBP-3), 67
Inter- and intracellular distribution, 57
Intracranial, 351
Invasion, 245, 465
Irinotecan, 361
Isobologram, 85
Isoflavene, 299

JNK signaling, 119

Keratinocytes, 325

Lactotransferring, 261
Laryngeal cancer, 273
Laryngeal carcinoma, 273
Leptin, 375
Lethal giant larvae, 431
Leukemia, 415
Lipid peroxidation, 167
Liposome, 351
Liposome delivery, 361
Locked nucleic acid, 157
Loss of heterozygosity (LOH), 261, 333
Low molecular weight heparin (LMWH), 245
Lung cancer, 49, 445
Lung metastasis, 15
Lymph node metastasis, 431
Lymphomyosot, 211

Malignant mesothelioma, 235
Mannan, 415
MAP kinase, 75
Maternal exposure, 383
MDR1, 395
Metastasis, 217, 465
Methotrexate, 415
Methylation, 261
1-Methylnicotinamide, 569
Microarrays, 535
Micro-PIXE, 57
Microsatellite marker, 333
MrDb, 549
MTA1, 465
Multicellular spheroid, 471
Mutation, 261
MYO18B, 235

NADH oxidase, 299, 557
Nasopharyngeal carcinoma, 261, 395
Neoplastic tumor suppressor genes, 431
NF-kB, 1
Nicotinamide, 569
Non-small cell lung cancer (NSCLC), 333, 375
N-oxide nicotinamide, 569
 
 

+12p11-p12, 405
p16, 572
p16^INK4a, 479
p21, 75
Paclitaxel, 507
Pantothenic acid, 389
Parthenolide, 1
Pathologic parameters, 205
Peritoneal dissemination, 289
Phenoxodiol, 299
Phenylephrine, 569
Phosphorylated prolactin, 75
Plasma membrane-associated sialidase, 289
Pleural effusion, 235
PML/RARa, 157
Poly[g-benzyl-L-glutamate] (PBLG), 313
Poly[ethylene glycol] (PEG), 313
Polymorphism(s), 423, 437
Poorly soluble drugs, 313
Positron emission tomography, 471
Premetrexed, 85
Primary cell cultures, 245
Prognosis, 205, 395
Prolactin, 75
Proliferating cell nuclear antigen, 167
Prostate cancer, 35, 341
Proteomics, 497
Pu-erh tea, 119

Quercetin, 67

Ras, 107
RASSF1A, 205
Rat tail artery, 569
Real-time RT-PCR, 535
Receptor tyrosine kinase, 179
Retinoblastoma protein (pRb), 527
Re-treatment, 489
Risk, 437
Risk factors, 383
RNA interference, 405
RT-PCR, 575

Selective estrogen receptor modulator (SERM), 251
Short-term treatment, 489
Sialidase, 289
Signal transduction, 179
siRNA, 507
Size distribution, 35
Skin cancer, 325
Solid tumors, 281
Soluble VEGF receptor 2(sVEGFR-2), 445
Splenocytes, 1
Synergism, 85
Synergistic action of vitamin B₅, 389
Synergy, 361
Systemic circle, 375

Tamoxifen, 251
Target validation, 549
TAT peptide, 351
Testicular neoplasms, 383
Thymosin-beta-4 (TB4), 507
TNF-a, 375
TNM classification, 289
tNOX, 299, 557
Tobacco smoking, 333
Transgenic mice, 325
Treatment, 211
Tryosinase, 97
Tumor cell lines, 143
Tumor necrosis factor (TNF), 1
Tumor suppressor, 179

U-87 MG astrocytoma, 351

Valproic acid, 453
Vascular endothelial growth factor (VEGF), 235
Vascular smooth muscle, 569
VEGF-C, 445
VEGF-D, 445
VEGFR, 15
Vitamin B₅, 389
Vitamin D receptor, 75